Legacy Flip

627article: Personalizing Myeloma Treatment Can Limit the Use of Expensive Drugs
627article: Case Report: Intense Maintenance in a Woman with High-Risk Multiple Myeloma
627article: Case Presentation: International Focus on the Management of Acral Lentiginous Melanoma
627article: Novel Therapeutics Targeting CD19 and CD22 in Adult Acute Lymphoblastic Leukemia
627article: Enthusiasm Mounts in the Personalized Medicine Movement
626article: Update on Vaccines
626article: The Future of Immunotherapy in Breast Cancer
626article: Will PD-1 Blockers Have a Role in Hematologic Cancers?
626article: Monoclonal Antibodies Poised to Be Blockbusters
626article: Immunotherapy Attacks Minimum Residual Disease in ALL; Leads to High Rate of Complete Response
626article: PD-1 Inhibitor–Based Immunotherapy the Newest Breakthrough in Hodgkin Lymphoma
626article: CAR T-Cell Therapy Achieves High Rate of Remission in Pediatric Relapsed/Refractory ALL
626article: Immune Checkpoint Blockades: The Future of Cancer Therapy
626article: FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (Anti–PD-L1) in Non–Small Cell Lung Cancer
626article: Commercial Availability of Anti–PD-1 Antibodies in Melanoma: A Benchmark of Success
626article: The Evolving Role of Immunotherapeutic Applications in Oncology
625article: The Management of Adverse Events: A Pharmacist’s Perspective
625article: Side Effect Management: A Nurse’s Perspective
625article: Advances in Side Effect Management
624article: Personalized Medicine’s Progress
624article: PMO Live: A Global Biomarkers Consortium Initiative
624article: World Cutaneous Malignancies Congress
624article: Putting the “Person” in Personalized Cancer Medicine: A Systematic Review of Psychological Aspects of Targeted Therapy
624article: Providing Therapeutic Guidance for Breast Cancer Patients in the Molecular Era With the Breast Cancer Index(SM) Assay:

An Interview with Stephen C. Malamud, MD, and Susan K. Boolbol, MD, of Mount Sinai Beth Israel Hospital

624article: Reflections on 2014 – Enthusiasm for 2015
623article: Access to Care: A Pharmacist’s Perspective
623article: Access to Quality Care: A Nurse’s Perspective
623article: Access to Care
622article: Immunotherapeutic Strategies for Improving Patient Outcomes: Presentations From the European Society for Medical Oncology
622article: New Drugs and Clinical Trial Data: Updates in Cutaneous Malignancies
622article: Targeted Agents, Immunotherapy, and Other Treatments Are Emerging for Cutaneous Malignancies
622article: Immunotherapy and the Moon Shots Program:

An Interview with Dr James Allison of MD Anderson Cancer Center

622article: Immunotherapy: Early Success in Melanoma Provides Hope for Success in Other Cancers
621article: Ensuring Safety of Compounded Sterile Products: A New Regulatory Framework
621article: Good Manufacturing Practice: A Pharmacist’s Perspective
621article: Good Manufacturing Practice: A Nurse’s Perspective
621article: Good Manufacturing Practice
619article: LH-RH Agonist Preserves Fertility When Added to Chemotherapy in Younger Breast Cancer Patients
619article: HER2-Derived Vaccine Cuts Recurrences in High-Risk Breast Cancer
619article: Record-Breaking Survival in HER2 Metastatic Breast Cancer
619article: Nivolumab: Impressive Responses in Melanoma
619article: Combo of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
619article: Novel Treatment-Specific Genetic Marker on the Horizon
619article: The Third Annual PMO Live: A Global Biomarkers Consortium Initiative
619article: The Third Annual World Cutaneous Malignancies Congress
619article: Predictors of Hormone Responsiveness in Prostate Cancer
619article: Persistence and the Expedition to Mine the Immune System for Cancer Cures:

An Interview with Dr James Allison of MD Anderson Cancer Center

619article: Personalized Medicine in Oncology Proudly Presents the Third Annual World Cutaneous Malignancies Congress and PMO Live: A Global Biomarkers Consortium Initiative
618article: A Focus on Polycythemia Vera and Myelofibrosis: Updates from ASCO and EHA 2014
617article: 2014 Oncology Pipeline Looks Impressive
617article: Cervical Cancer: Beyond Today’s HPV Vaccine
617article: Cytokines as Immune Adjuvants for Treating Cancer
617article: Immunotherapy in Colorectal Cancer: Present and Future
617article: Case Studies in Immunotherapy
617article: First Anti–PD-1 Immunotherapy, Pembrolizumab, Receives Accelerated FDA Approval for Advanced Melanoma
616article: The Personalized Medicine Coalition and Turning the Tide Against Cancer Through Sustained Medical Innovation
616article: Determining the Value of Cancer Therapies: A Paradigm Shift Focused on Quality, Outcomes, and Cost
616article: Patients Want But Aren’t Getting Up-Front Discussions About the Cost of Their Cancer Therapy
616article: Ramucirumab Conveys Survival Benefit in NSCLC
616article: Are Hospital Readmissions for Cancer Patients Preventable?
616article: Cancer Patients, By and Large, Not Pursuing Costly, Excessive Tests
616article: Routine Imaging Costly in B-Cell Lymphoma but Rarely Picks Up Relapse After Remission
616article: Pharmacokinetic-Guided Dosing of 5-FU Shown Cost-Effective
616article: ASCO Workgroup Proposes Consolidated Payments for Oncology Care
616article: What Makes a Treatment “Clinically Meaningful”?
616article: Navigating the Molecular Testing Landscape in Lung Cancer
616article: Highlights From the 6th International Symposium on Acute Promyelocytic Leukemia
616article: FDA Approves Pembrolizumab for Advanced Melanoma
616article: Tissue Phenomics: Closing the Gap Between Genomic Information and Patient Outcomes
616article: PMO: Recognizing the Many Principles Governing the Personalized Medicine Movement
615article: The Case for Personalized Medicine: Defining the Field and Envisioning the Future of Healthcare
615article: Value-Based Insurance – Not Such an Easy Sell
615article: Enthusiasm High for Anti­–PD-1 Agents
615article: Bevacizumab Not Cost-Effective in Metastatic Colorectal Cancer
615article: Anti–PD-1 Antibodies in NSCLC and Renal Cell Carcinoma
615article: Ibrutinib Tops Ofatumumab as Second-Line Therapy for CLL
615article: Oncologists Want to Discuss Cost of Treatments With Patients but Believe They Are Not Well Equipped to Do So
615article: Less May Be More With Zoledronic Acid
615article: Federal Spending on Cancer Research and Access to Care Called Woefully Inadequate by ASCO President
615article: PSA Trend Analysis May Help Avoid Unnecessary Biopsies
615article: Improved Survival With Antiandrogen After ADT in Metastatic CRPC
615article: Blocking Immune Checkpoints in Metastatic Melanoma
615article: RAS and Colon Cancer: What You’re Missing
615article: Personalized Medicine and Value:

An Interview with Faculty at the Fourth Annual Conference of the Association for Value-Based Cancer Care

615article: PMO: Advancing the Practitioner’s Ability to Provide Customized Care to Patients
613article: IDO: A Target for Cancer Treatment
613article: The Treatment of Relapsed Metastatic Melanoma Using a Novel Immunotherapy Combination:

An Interview with Mario Sznol, MD

613article: Nivolumab, a Novel Anti–PD-1 Monoclonal Antibody for the Treatment of Solid and Hematologic Malignancies
613article: Immuno-Oncology Takes Center Stage
613article: Immune-Related Endocrinopathies Associated with Ipilimumab Therapy
613article: Oncolytic Viruses for the Treatment of Advanced Melanoma
613article: Immunotherapy Holds Promise to Extend Survival in GI Cancers
611article: FGFR Inhibitor Shows Promising Anticancer Activity
611article: Hormonal Therapy for Prostate Cancer: An Oncologist’s Perspective
611article: Simple Blood Test Predicts Response to Enzalutamide in Patients With Prostate Cancer
611article: Potential New Approach to Treatment of Melanoma
611article: Immuno-Oncology Takes Center Stage at ASCO 2014
611article: Highest Response Rate to Date With a Third-Line VEGF Inhibitor, Pazopanib, in Metastatic Renal Cell Carcinoma
611article: Molecular Diversity of CLL
611article: PMO and the PMC – A Collaboration to Advance Precision Medicine